Heartflow falls 5% after posting Q3 loss
Heartflow (HTFL) reported Q3 revenue of $72.9M, up 57% YoY, and adjusted loss per share of -$0.03, beating estimates. The company raised 2026 revenue guidance to $262M-$264M. Shares fell 5% post-earnings.
How this was made
The 30-second read
Why it matters
Earnings beat on loss and strong revenue growth were offset by a modest share decline, suggesting mixed market reaction.
Market read
The Q3 earnings and raised guidance are the primary catalyst for the stock's 5% decline, offering a short‑term trading signal.
What to watch
AI‑driven efficiency gains and expanding international revenue could drive future margin improvement.
Background
Heartflow is a medical‑technology company offering non‑invasive coronary artery disease diagnostics.
Ticker impact
Q3 results showed an adjusted loss of $0.03 per share and revenue of $72.9M, with full‑year 2026 revenue guidance raised to $262‑264M; shares fell 5% after the release.
likely downward pressure as the market digests the modest loss despite higher guidance
The stock dropped 5% on the news, indicating traders are reacting negatively to the earnings despite the raised outlook.
Market effects
Highlights growing demand for cardiac diagnostic platforms, but may temper enthusiasm for similar small‑cap med‑tech stocks.
Primarily affects US biotech/med‑tech investors; limited broader market effect.
Limited to niche healthcare investors; no major macro impact.
Counterpoint
The raised guidance could signal longer‑term upside; the short‑term sell‑off may present a buying opportunity.
Key entities
- personJohn Farquhar
President and CEO of Heartflow, quoted on the earnings release.
